Pfizer: 3 Key Takeaways for Long-Term Investors
Pfizer raised its full-year 2026 revenue outlook to $62 billion to $64 billion on its third-quarter earnings call. [[fact-kpbjkacic]] CEO Albert Bourla said the company's launched and acquired products generated 32% operational revenue growth in the quarter. [[fact-2e62c4hg8]] The CFO said Pfizer remained on track to deliver nearly all of its anticipated $7.2 billion in net savings by the end of 2026. [[fact-08evskkpz]] Pfizer faces loss of exclusivity or patent expirations on key commercial drugs later this decade. [[fact-f1cqim2zb]] Bourla said Pfizer had line of sight to its aim of risk-adjusted high-single-digit revenue CAGR from year-end 2028 through year-end 2033. [[fact-m87jsttjj]] Pfizer's chief scientific officer said the company expects a strong cadence of regulatory decisions, data readouts, and pivotal study starts over the next 12 months. [[fact-b075p63b3]]